Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11520 posts found.

bayercross3

Bayer’s Jivi approved in Europe for previously treated haemophilia A

November 28, 2018 Research and Development, Sales and Marketing Bayer, Jivi, haemophilia, pharma

Bayer has revealed that its recombinant Factor VIII (rFVIII) replacement therapy Jivi, also known as BAY94-9027, has received approval from …
News
takeda_usa_pharmaceuticals_u

European approval for Takeda’s Alunbrig in ALK+ advanced non-small cell lung cancer

November 27, 2018 Research and Development, Sales and Marketing Alunbrig, Cancer, Takeda, lung cancer, pharma

Takeda’s Alunbrig (brigatinib) has been granted marketing approval by the European Commission as a monotherapy to treat anaplastic lymphoma kinase-positive …
News
shutterstock_87495637

Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz

November 27, 2018 Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma

The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …
News
nhs_sign

NHS to save £300 million by switching to Humira biosimilars

November 27, 2018 Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
News
fda2outsideweb

FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi

November 27, 2018 Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma

The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …
News
shutterstock_57369385

European Commission approves first and only long-acting opioid dependence therapy

November 26, 2018 Sales and Marketing Europe, opioid crisis, opioids, pharma

Europe has seen its first and only approval of a long-acting therapy for opioid dependence, as the European Commission (EC) …
News
sunpharma

Sun Pharma’s New Jersey manufacturing overhaul puts 96 jobs at risk

November 26, 2018 Manufacturing and Production, Sales and Marketing Sun Pharma, manufacturing, pharma

Indian pharma firm Sun Pharma has announced it is to combine its New Jersey manufacturing operations in a bid to …
News
opioid_crisis

Opioid use disorder market to hit $4.8 billion by 2027, says GlobalData

November 26, 2018 Sales and Marketing US, opioid crisis, opioids, pharma

New findings released by analytics firm GlobalData indicates that the market for opioid use disorder therapies is set to grow …
News
novo_nordisk_flag

Novo Nordisk’s semaglutide meets primary endpoint of reducing cardiovascular events at Phase 3

November 26, 2018 Research and Development, Sales and Marketing Novo Nordisk, diabetes, pharma, semaglutide

Novo Nordisk has revealed new Phase 3a data for its investigational GLP-1 analogue therapy semaglutide, showing that the drug met …
News
european_commission_web

Mundipharma’s Neulasta biosimilar approved in EU

November 26, 2018 Sales and Marketing Amgen, EU, Europe, Mundipharma, Neulasta, Pelmeg, pharma

Mundipharma has revealed that Pelmeg, its biosimilar version of Amgen’s Neulasta (pegfilgrastim), has been awarded marketing approval by the European …
News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 23, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kymriah, Mundipharma, UK, US, brexit, pharma, politics, top 10

The appointment of GSK veteran Arnaud Breabout to the position of Senior Vice President and CFO of Mundipharma took the …
News
novartis_window

Novartis’ gene therapy Luxturna becomes first approved European therapy for vision loss subtype

November 23, 2018 Medical Communications, Sales and Marketing EU, Europe, Luxturna, Novartis, pharma, vision loss

Novartis has revealed that its one-time gene therapy Luxturna (voretigene neparvovec) has been awarded approval by the European Commission to …
News

Pfizer’s Daurismo becomes first of its kind to secure FDA approval in acute myeloid leukaemia

November 22, 2018 Research and Development, Sales and Marketing AML, Daurismo, FDA, Pfizer, US, leukaemia

Pfizer has revealed that the FDA has chosen to approve its Daurismo (glasdegib) for the treatment of newly-diagnosed acute myeloid …
News

Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer

November 22, 2018 Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma

MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
News

Uninsured patients elibible for no-cost replacement of medicines lost in California wildfires

November 22, 2018 Manufacturing and Production, Sales and Marketing USA, california, insurance, prescription, wildfires

Uninsured citizens in California’s Butte, Los Angeles and Ventura counties will be eligible for a no-cost replacement of medicines lost …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025